4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Neurogene Inc. (NGNE) operates in the Biotechnology industry and is headquartered in New York, United States with about 131 employees. Its market capitalization is roughly $745 million. In the fiscal year ended 2025-12-31, NGNE reported $0M in revenue and ($90M) in net income.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $1M | $0M | $0M |
| Operating Income (EBIT) | ($103M) | ($83M) | ($56M) | ($56M) |
| Net Income | ($90M) | ($75M) | ($36M) | ($55M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($33M) | ($28M) | ($24M) | ($26M) | ($26M) |
| Net Income | ($31M) | ($25M) | ($21M) | ($22M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $289M | $336M | $223M | $109M | — |
| Total Liabilities | $24M | $25M | $36M | $255M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NGNE viewer.
About TickerBase · Data methodology & sources